Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Medical Economics|March 5, 2015
Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancerRobert Hettle, John Posnett, John Borrill
Clinicoeconomics and Outcomes Research : CEOR|December 10, 2015
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithmsRobert Hettle, John Borrill, Gaurav Suri, et al.
International Journal of Technology Assessment in Health Care|July 4, 2020
Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisalsDemi Radeva, Gareth Hopkin, Elias Mossialos, et al.
International Journal of Technology Assessment in Health Care|March 25, 2022
A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health AuthoritiesValentine Grumberg, Stéphane Roze, Julie Chevalier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 21, 2024
Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling SuggestionsMathilde Puls, James Horscroft, Benjamin Kearns, et al.
Pharmacoeconomics|January 11, 2021
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell CarcinomaSven L Klijn, Elisabeth Fenwick, Sonja Kroep, et al.
Pharmacoeconomics - Open|July 3, 2021
Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision MakingJason Gordon, Angela Stainthorpe, Beverley Jones, et al.
Pharmacoeconomics|September 20, 2024
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?Nicholas R Latimer, Kurt Taylor, Anthony J Hatswell, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell CarcinomaShannon Cope, Keith Chan, Harlan Campbell, et al.
MDM Policy & Practice|March 31, 2022
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced MelanomaVictoria Federico Paly, Murat Kurt, Lirong Zhang, et al.
Pageof 2